 |
Case Report
Metastatic teratoma in a young female: A rare case of bowel involvement
1 MBBS, FCPS Part 1, Resident, Obstetrics and Gynecology, Dow University of Health Sciences, Karachi, Sindh, Pakistan
2 MBBS, House Officer, Obstetrics and Gynecology, Dow University of Health Sciences, Karachi, Sindh, Pakistan
3 MBBS, Student, Obstetrics and Gynecology, Dow University of Health Sciences, Karachi, Sindh, Pakistan
Address correspondence to:
Muhammad Mustafa
House no. 3/109, Street no. 10, Maqboolabad, Bahadurabad, Karachi East, Karachi, Sindh,
Pakistan
Message to Corresponding Author
Article ID: 100205Z08KM2025
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Memon KJ, Ahsan A, Farooqui T, Mahboob H, Mustafa M. Metastatic teratoma in a young female: A rare case of bowel involvement. J Case Rep Images Obstet Gynecol 2025;11(1):83–88.ABSTRACT
Introduction: Teratocarcinoma is a type of germ cell tumor that can occur in the ovaries or testes. It has features of both teratoma and carcinoma. It is considered a malignant tumor and can be aggressive, sometimes spreading to other parts of the body, such as the peritoneum. Treatment typically involves a combination of surgery and chemotherapy, although the tumor’s response to treatment can vary.
Case Report: This article discusses a rare instance of ovarian teratocarcinoma with peritoneal metastasis that is unresponsive to chemotherapy in a 24-year-old female patient. The patient has a positive family history of hepatocellular carcinoma. The patient underwent two sessions of chemotherapy but the tumor was unresponsive and the β-human chorionic gonadotropin (β-hCG) levels kept rising but a-fetoprotein levels decreased. Discussion: The diagnosis of teratocarcinoma in this case was hypothesized on histopathologic examination. Its heterogeneity was demonstrated by the aggressive behavior of bulky peritoneal carcinomatosis and resistance to the treatment. Throughout the clinical course this teratocarcinoma was resistant to bleomycin, cisplatin, etoposide (BEP) and paclitaxel, cisplatin, ifosfamide, and mesna (TIP) regimens which allows for in depth exploration of unique teratocarcinoma care.
Conclusion: This case exemplifies that rare cases of ovarian teratocarcinoma are chemotherapy resistant and difficult to treat hence new and better treatment strategies should be explored.
Keywords: Carcinoma, Germ cell tumor, Peritoneal metastasis, Teratoma
SUPPORTING INFORMATION
Author Contributions
Kanwal Jan Memon - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Aiman Ahsan - Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Final approval of the version to be published
Tehreem Farooqui - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Haniah Mahboob - Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Muhammad Mustafa - Substantial contributions to conception and design, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2025 Kanwal Jan Memon et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
